-
Reproductive Sciences (Thousand Oaks,... Sep 2021Long non-coding RNAs (lncRNAs) are emerging regulators of cellular pathways, especially in cancer development. Among the lncRNAs, nuclear paraspeckle assembly transcript...
Long non-coding RNAs (lncRNAs) are emerging regulators of cellular pathways, especially in cancer development. Among the lncRNAs, nuclear paraspeckle assembly transcript 1 (NEAT1) forms a scaffold for a nuclear body; the paraspeckle and aberrant expression of NEAT1 have been reported in breast and gynecologic cancers (ovarian, cervical, endometrial, and vulvar). Abundantly expressed NEAT1 in breast and gynecologic cancers generally contribute to tumor development by sponging its corresponding tumor-suppressive microRNAs or interacting with various regulatory proteins. The distinct expression of NEAT1 and its contribution to tumorigenic pathways make it a promising therapeutic target in breast and gynecologic cancers. Herein, we summarize the functions and molecular mechanisms of NEAT1 in human breast, ovarian, cervical, endometrial, and vulvar cancers. Furthermore, we emphasize its critical role in the formation of paraspeckle development and its functions. Conclusively, NEAT1 is a considerable biomarker with a bright prospect and can be therapeutically targeted to manage breast and gynecologic cancers.
Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Clinical Decision-Making; Female; Gene Expression Regulation, Neoplastic; Genital Neoplasms, Female; Humans; Ovarian Neoplasms; Precision Medicine; Predictive Value of Tests; Prognosis; RNA, Long Noncoding; Signal Transduction; Uterine Neoplasms; Vulvar Neoplasms
PubMed: 33569749
DOI: 10.1007/s43032-021-00481-x -
Expert Review of Molecular Diagnostics Jan 2021Nuclear paraspeckle assembly transcript 1 (NEAT1), a newly found lncRNA, is found abnormally expressed in digestive system tumors. This meta-analysis aims to evaluate... (Meta-Analysis)
Meta-Analysis
OBJECTIVE
Nuclear paraspeckle assembly transcript 1 (NEAT1), a newly found lncRNA, is found abnormally expressed in digestive system tumors. This meta-analysis aims to evaluate the effect of NEAT1 on digestive system tumors.
METHODS
An analysis was conducted to investigate NEAT1 expression in digestive system tumors from the PubMed, Embase, and Web of Science databases. The relationship between NEAT1 expression and patient overall survival (OS) and clinicopathology was evaluated by correlation analysis with the pooled hazard ratio (HR), 95% confidence interval (CI), and odds ratio (OR).
RESULTS
A total of 12 published studies were enrolled in this meta-analysis. The NEAT1 overexpression was significantly associated with poor OS (HR = 1.64, 95% CI:1.41-1.91, < 0.05), lymphatic metastasis (OR = 2.70, 95% CI: 2.02-3.61, < 0.05), distal metastasis (OR = 3.01, 95% CI: 1.97-4.59, < 0.05) and advanced tumor stage (OR = 3.04, 95% CI: 2.32-3.99, < 0.05). However, digestive system tumor patients with high NEAT1 expression was not related to the patients' age (OR = 0.91, 95% CI: 0.65-1.26, = 0.561), gender (OR = 1.04, 95% CI: 0.81-1.33, = 0.761), tumor size (OR = 1.84, 95% CI: 0.88-3.88, = 0.106), and tumor differentiation (OR = 0.86, 95% CI: 0.51-1.44, = 0.570).
CONCLUSION
Collectively, NEAT1 can be used as a potential biomarker to predict the prognosis of patients with digestive system tumors, which is worth verifying in clinical practice.
Topics: Biomarkers; Digestive System Neoplasms; Humans; Prognosis; RNA, Long Noncoding
PubMed: 33550874
DOI: 10.1080/14737159.2021.1874921 -
Oncotarget Jan 2017Long non-coding RNAs (lncRNAs) are playing important roles in cancer progression and metastasis. Recent studies have demonstrated that the lncRNA, nuclear paraspeckle... (Meta-Analysis)
Meta-Analysis Review
OBJECTIVES
Long non-coding RNAs (lncRNAs) are playing important roles in cancer progression and metastasis. Recent studies have demonstrated that the lncRNA, nuclear paraspeckle assembly transcript 1 (NEAT1), was aberrantly up-regulated in various types of cancers and was reported to be associated with unfavorable prognosis in cancer patients. This study examined the relationship between NEAT1 and relevant clinical outcomes.
RESULTS
A total of 1354 patients from 11 eligible studies were included in the meta-analysis. The results showed that high expression level of NEAT1 was significantly associated with shorter overall survival in cancer patients (hazard ratio (HR) = 1.53, 95% confidence interval (CI) = 1.36-1.71); in the subgroup analysis, the positive association was also found in patients with hepato-gastroenterol cancers (HR = 1.79, 95% CI = 1.48-2.16), non-small cell lung cancer (HR = 1.35, 95% CI = 1.04-1.76), ovarian cancer (HR = 1.41, 95% CI = 1.11-1.79) and other types of cancers (HR = 1.42, 95% CI = 1.11-1.81). The clinicopathological parameters analysis further showed that increased expression level of NEAT1 was positively correlated with larger tumor size (odds ratio (OR) = 1.74, 95% CI = 1.26-2.41), lymph node metastasis (OR = 2.29, 95% CI = 1.71-3.06), advanced TNM stage (OR = 3.60, 95% CI = 2.27-5.72), poor tumor differentiation (OR = 2.16, 95% CI = 1.58-2.93), distant metastasis (OR = 3.51, 95% CI = 1.75-7.01), and invasion depth (OR = 1.94, 95% CI = 1.36-2.75).
MATERIALS AND METHODS
A comprehensive search was performed in Pubmed, Embase, Web of Science and CNKI databases, and eligible studies were included based on defined exclusion and inclusion criteria to perform meta-analysis.
CONCLUSIONS
The meta-analysis results from present study suggested that increased expression level of NEAT1 was associated with unfavorable prognosis and may serve as a predictive factor for clinicopathological features in various cancers.
Topics: Biomarkers, Tumor; Gene Expression; Humans; Neoplasm Grading; Neoplasm Staging; Neoplasms; Odds Ratio; Prognosis; Proportional Hazards Models; Publication Bias; RNA, Long Noncoding; Tumor Burden
PubMed: 27926523
DOI: 10.18632/oncotarget.13737